AARTI PHARMALABS Latest Share Price (AARTIPHARM)
TODAY IN ONE LINE
AARTIPHARM fell 1.7% on above-average volume (2.1x avg), lagging Nifty's -0.5% move.
With a market cap of ₹7,537.76 Cr., it trades at a P/E of 35.25. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
AARTI PHARMALABS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 16.5%
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 30.8% YoY
- ●Poor Capital ReturnsLow ROE of 9.5%
- ●Promoter SellingPromoter holding decreased by 3.20% QoQ
Latest AARTI PHARMALABS News
What changed recently?
Recent events, corporate actions, and announcements.
AARTI PHARMALABS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for AARTI PHARMALABS, framed against the sector median so the premium or discount is obvious at a glance.
AARTI PHARMALABS trades at a P/E of 35.25× and P/B of 3.55×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
AARTI PHARMALABS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for AARTI PHARMALABS — derived from the latest tape, not yesterday's close.
AARTI PHARMALABS last traded at ₹828.8 with an intraday range of ₹821–₹844 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹828.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 887.53 | +58.73 | +7.09% |
| R3 | 864.53 | +35.73 | +4.31% |
| R2 | 854.27 | +25.47 | +3.07% |
| R1 | 841.53 | +12.73 | +1.54% |
| PIVOT | 831.27 | 2.47 | 0.30% |
| CURRENT | 828.80 | — | — |
| S1 | 818.53 | -10.27 | -1.24% |
| S2 | 808.27 | -20.53 | -2.48% |
| S3 | 795.53 | -33.27 | -4.01% |
| S4 | 772.53 | -56.27 | -6.79% |
AARTIPHARM is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹825.6–₹844
Trading Inside opening range
AARTI PHARMALABS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for AARTI PHARMALABS — consolidated or standalone — with margins, YoY growth and key ratios inline.
AARTI PHARMALABS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹7,537.76 Cr. and reported EPS of ₹23.50.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 1,819 | 1,819 ▲ 0.0% |
| Sales Growth YoY %Derived | -13.98% | -13.98% |
| Other Income | 10 | 10 ▲ 0.0% |
| Total Income | 1,829 | 1,829 ▲ 0.0% |
| 835 | 835 ▲ 0.0% | |
| Gross ProfitDerived | 985 | 985 ▲ 0.0% |
| Gross Margin %Derived | 54.12% | 54.12% |
| 615 | 615 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 369 | 369 ▲ 0.0% |
| OPM %Derived | 20.29% | 20.29% |
| 148 | 148 ▲ 0.0% | |
| Profit Before Tax (PBT) | 225 | 225 ▲ 0.0% |
| 58 | 58 ▲ 0.0% | |
| Effective Tax %Derived | 25.88% | 25.88% |
| Total Profit for Period | 175 | 175 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 175 | 175 ▲ 0.0% |
| Net Profit Margin %Derived | 9.60% | 9.60% |
| PAT Growth YoY %Derived | -35.86% | -35.86% |
| Earnings Per Share (EPS ₹) | 19.27 | 19.27 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% |
| Share of Profit from Associates/JVs | 8 | 8 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -6 | -6 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 1,604 | 1,604 ▲ 0.0% |
| Material Cost % of RevenueDerived | 45.62% | 45.62% |
| Employee Cost % of RevenueDerived | 9.51% | 9.51% |
| Other Cost % of RevenueDerived | 24.31% | 24.31% |
| Interest Coverage (x)Derived | 5.65x | 5.65x |
| Period | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,945 | 1,945 ▲ 0.0% | 1,853 ▼ 4.8% | 1,853 ▲ 0.0% | 2,115 ▲ 14.2% | 2,115 ▲ 0.0% | 1,819 ▼ 14.0% | 1,819 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | -4.76% | -4.76% | 14.17% | 14.17% | -13.98% | -13.98% | |
| Other Income | 2 | 2 ▲ 0.0% | 5 ▲ 111.0% | 5 ▲ 0.0% | 10 ▲ 106.7% | 10 ▲ 0.0% | 10 ▼ 3.7% | 10 ▲ 0.0% | |
| Total Income | 1,948 | 1,948 ▲ 0.0% | 1,858 ▼ 4.6% | 1,858 ▲ 0.0% | 2,125 ▲ 14.4% | 2,125 ▲ 0.0% | 1,829 ▼ 13.9% | 1,829 ▲ 0.0% | |
1,170 | 1,170 ▲ 0.0% | 1,021 ▼ 12.7% | 1,021 ▲ 0.0% | 1,128 ▲ 10.5% | 1,128 ▲ 0.0% | 835 ▼ 26.0% | 835 ▲ 0.0% | ||
| Gross ProfitDerived | 775 | 775 ▲ 0.0% | 832 ▲ 7.3% | 832 ▲ 0.0% | 987 ▲ 18.7% | 987 ▲ 0.0% | 985 ▼ 0.3% | 985 ▲ 0.0% | |
| Gross Margin %Derived | 39.87% | 39.87% | 44.90% | 44.90% | 46.67% | 46.67% | 54.12% | 54.12% | |
433 | 433 ▲ 0.0% | 446 ▲ 2.9% | 446 ▲ 0.0% | 523 ▲ 17.3% | 523 ▲ 0.0% | 615 ▲ 17.7% | 615 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 342 | 342 ▲ 0.0% | 386 ▲ 12.9% | 386 ▲ 0.0% | 464 ▲ 20.3% | 464 ▲ 0.0% | 369 ▼ 20.5% | 369 ▲ 0.0% | |
| OPM %Derived | 17.58% | 17.58% | 20.84% | 20.84% | 21.96% | 21.96% | 20.29% | 20.29% | |
84 | 84 ▲ 0.0% | 90 ▲ 8.2% | 90 ▲ 0.0% | 114 ▲ 25.8% | 114 ▲ 0.0% | 148 ▲ 30.4% | 148 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 261 | 261 ▲ 0.0% | 300 ▲ 15.2% | 300 ▲ 0.0% | 361 ▲ 20.0% | 361 ▲ 0.0% | 225 ▼ 37.6% | 225 ▲ 0.0% | |
67 | 67 ▲ 0.0% | 84 ▲ 24.2% | 84 ▲ 0.0% | 88 ▲ 5.6% | 88 ▲ 0.0% | 58 ▼ 34.1% | 58 ▲ 0.0% | ||
| Effective Tax %Derived | 25.80% | 25.80% | 27.82% | 27.82% | 24.48% | 24.48% | 25.88% | 25.88% | |
| Total Profit for Period | 193 | 193 ▲ 0.0% | 217 ▲ 12.1% | 217 ▲ 0.0% | 272 ▲ 25.6% | 272 ▲ 0.0% | 175 ▼ 35.9% | 175 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 193 | 193 ▲ 0.0% | 217 ▲ 12.1% | 217 ▲ 0.0% | 272 ▲ 25.6% | 272 ▲ 0.0% | 175 ▼ 35.9% | 175 ▲ 0.0% | |
| Net Profit Margin %Derived | 9.95% | 9.95% | 11.71% | 11.71% | 12.88% | 12.88% | 9.60% | 9.60% | |
| PAT Growth YoY %Derived | — | — | 12.10% | 12.10% | 25.59% | 25.59% | -35.86% | -35.86% | |
| Earnings Per Share (EPS ₹) | 21.35 | 21.35 ▲ 0.0% | 23.88 ▲ 11.9% | 23.88 ▲ 0.0% | 30.06 ▲ 25.9% | 30.06 ▲ 0.0% | 19.27 ▼ 35.9% | 19.27 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | 8 | 8 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -3 | -3 ▲ 0.0% | -0 ▲ 86.9% | -0 ▲ 0.0% | -10 ▼ 2062.5% | -10 ▲ 0.0% | -6 ▲ 36.1% | -6 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 1,687 | 1,687 ▲ 0.0% | 1,557 ▼ 7.7% | 1,557 ▲ 0.0% | 1,765 ▲ 13.3% | 1,765 ▲ 0.0% | 1,604 ▼ 9.1% | 1,604 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 52.14% | 52.14% | 46.34% | 46.34% | 41.94% | 41.94% | 45.62% | 45.62% | |
| Employee Cost % of RevenueDerived | 6.67% | 6.67% | 7.47% | 7.47% | 7.66% | 7.66% | 9.51% | 9.51% | |
| Other Cost % of RevenueDerived | 15.61% | 15.61% | 16.59% | 16.59% | 17.06% | 17.06% | 24.31% | 24.31% | |
| Interest Coverage (x)Derived | 13.28x | 13.28x | 18.17x | 18.17x | 14.03x | 14.03x | 5.65x | 5.65x |
AARTI PHARMALABS segment analysis : revenue and profit mix.
Disclosed business segments at AARTI PHARMALABS with their share of revenue and profit, switchable between consolidated and standalone reporting.
AARTI PHARMALABS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for AARTI PHARMALABS.
Our AI distills the core fundamental drivers supporting AARTI PHARMALABS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
AARTI PHARMALABS's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Low debt-to-equity ratio of D/E 0.35x offers strong financial flexibility.
Current ratio of 1.51x in FY2026 indicates adequate short-term liquidity.
Operating cash flow of ₹256.13 Cr in FY2026 shows strong cash conversion.
Promoter holding at 42.69% signals strong management alignment and commitment.
Diverse portfolio of APIs and CDMO services caters to broad medical needs.
Key Risks.
FY2026 net profit declined 31.45% YoY, indicating severe earnings contraction.
Free cash flow was negative -₹167.89 Cr in FY2026 due to heavy capex.
ROE 9.48% and ROCE 8.38% lag calculated peer medians.
Operating profit margin compressed to 20.59% in FY2026, indicating margin pressure.
Latest quarterly EPS declined 30.8% YoY, reflecting operational stress.
Flip Conditions.
Valuation risk. a P/E above 46 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
AARTI PHARMALABS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — AARTI PHARMALABS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
AARTI PHARMALABS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for AARTI PHARMALABS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
AARTI PHARMALABS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for AARTI PHARMALABS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in AARTI PHARMALABS stood at 49.6% of traded volume, against a 20-day average of 42.4%.
AARTI PHARMALABS announcements: results, concalls, ratings, M&A.
Filings AARTI PHARMALABS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
AARTI PHARMALABS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 133 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Aarti Pharmalabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Aarti Pharmalabs Limited has informed the Exchange about Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements)…
Updates
Aarti Pharmalabs Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI Listing Regulations- Reconstitution of Committee…
Trading Window
Aarti Pharmalabs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Updates
Aarti Pharmalabs Limited has informed the Exchange regarding 'Updates on Change in Directorate'.
Investor decks & rating reports.
AARTI PHARMALABS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue AARTI PHARMALABS has declared, sequenced by announce and record date.
AARTI PHARMALABS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
AARTI PHARMALABS insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in AARTI PHARMALABS as reported to SEBI — buying and selling signals from the people who know the business best.
AARTI PHARMALABS insider activity below tracks 23 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Tulip Family Trust | Insider | 12 Jun 2025 | sell | −25.0 K | ₹2.33 Cr. | ₹933.39 |
| Orchid Family Trust | Insider | 11 Jun 2025 | sell | −30.0 K | ₹2.78 Cr. | ₹927.52 |
| Orchid Family Trust | Insider | 06 Jun 2025 | sell | −20.0 K | ₹1.85 Cr. | ₹926.16 |
| Tulip Family Trust | Insider | 06 Jun 2025 | sell | −40.0 K | ₹3.68 Cr. | ₹919.11 |
| Orchid Family Trust | Insider | 30 May 2025 | sell | −20.0 K | ₹1.78 Cr. | ₹889.31 |
| Orchid Family Trust | Insider | 30 May 2025 | sell | −20.0 K | ₹1.82 Cr. | ₹909.98 |
| Tulip Family Trust | Insider | 30 May 2025 | sell | −40.0 K | ₹3.56 Cr. | ₹890.59 |
| Orchid Family Trust | Insider | 28 May 2025 | sell | −30.0 K | ₹2.64 Cr. | ₹878.74 |
| Tulip Family Trust | Insider | 28 May 2025 | sell | −20.0 K | ₹1.76 Cr. | ₹881.47 |
| Narendra J Salvi | Insider | 21 May 2025 | sell | −6.0 K | ₹50.49 L | ₹841.46 |
About AARTI PHARMALABS: business, sector, key facts.
What AARTI PHARMALABS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
AARTI PHARMALABS operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AARTIPHARM, BSE: 543748.
Aarti Pharmalabs Limited is a prominent Indian pharmaceutical company specializing in the manufacturing and global distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. Their diverse portfolio caters to a wide range of therapeutic areas, contributing to the production of various medications.
The company's API production supports a broad spectrum of medical needs, including cardiovascular health, asthma treatment, cancer therapies, anticoagulants, diabetes management, arthritis care, central nervous system (CNS) agents, skincare products, overactive bladder treatments, calcimimetics, decongestants, anti-thalassemics, analgesics, and ophthalmologic medications. This wide-ranging production demonstrates a commitment to addressing diverse health concerns through the supply of essential pharmaceutical components.
Beyond API production, Aarti Pharmalabs also offers contract development and manufacturing services (CDMO) for drug substance projects. This service caters to other pharmaceutical companies needing assistance with the development and production of their drug substances, expanding the company's role in the pharmaceutical industry beyond its own product lines.
Further strengthening their market presence, the company manufactures and sells a variety of intermediates and xanthine derivatives. These include crucial compounds like caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline, showcasing expertise in specialized chemical synthesis. In addition, they produce acidic and allied products, such as sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate, demonstrating a comprehensive range of chemical manufacturing capabilities.
Established in 2019 and headquartered in Mumbai, India, Aarti Pharmalabs Limited, previously known as Aarti Organics Limited, has rapidly established itself as a significant player in the global pharmaceutical supply chain, leveraging its extensive manufacturing capabilities and diverse product portfolio to meet the growing demand for high-quality pharmaceutical ingredients worldwide.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- ALBERT DAVID (ALBERTDAVD) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about AARTI PHARMALABS (AARTIPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of AARTI PHARMALABS (AARTIPHARM)?
The current share price of AARTI PHARMALABS (AARTIPHARM) is ₹828.80. Today, the stock has declined by ₹14.45 (1.71%), trading in a range of ₹821.00 to ₹844.00. The stock opened at ₹840.00 with a trading volume of 4,14,639 shares.
02Is AARTI PHARMALABS stock a good investment for long-term?
AARTI PHARMALABS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹7,537.76 Cr., P/E ratio of 35.25, ROE of 9.48%, and ROCE of 8.38%. The dividend yield stands at 0.48%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of AARTI PHARMALABS stock?
The 52-week high price of AARTI PHARMALABS (AARTIPHARM) is ₹1,002.40, while the 52-week low is ₹585.00. Currently trading at ₹828.80, the stock is 41.68% above its 52-week low and 17.32% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy AARTI PHARMALABS stock at the current price?
Whether to buy AARTI PHARMALABS stock at ₹828.80 depends on multiple factors. The stock is currently trading with a P/E ratio of 35.25 and P/B ratio of 3.55. Today's performance shows a loss of 1.71%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of AARTI PHARMALABS and when is the next dividend?
AARTI PHARMALABS offers a dividend yield of 0.48%, which means for every ₹100 invested at the current price of ₹828.80, you can expect to receive approximately ₹0.48 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of AARTI PHARMALABS?
AARTI PHARMALABS's key financial metrics include: P/E Ratio: 35.25, P/B Ratio: 3.55, ROE: 9.48%, ROCE: 8.38%, Dividend Yield: 0.48%, EPS: ₹23.50, Book Value: ₹234.28, and Debt-to-Equity: 0.35. The company's market cap stands at ₹7,537.76 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is AARTI PHARMALABS stock performing today in the market?
AARTI PHARMALABS stock opened at ₹840.00 and is currently trading at ₹828.80, showing a decline of ₹14.45 (1.71%). The intraday high is ₹844.00 and low is ₹821.00. The trading volume stands at 4,14,639 shares, indicating moderate market participation today.
08What is the P/E ratio of AARTI PHARMALABS and what does it indicate?
AARTI PHARMALABS has a Price-to-Earnings (P/E) ratio of 35.25, which means investors are willing to pay 35.25 for every ₹1 of earnings. With an EPS of ₹23.50, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about AARTI PHARMALABS (AARTIPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.